Iambic Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 171

Employees

  • Stock Symbol
  • IAM

Stock Symbol

  • Share Price
  • $13.05
  • (As of Friday Closing)

Iambic General Information

Description

Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.

Contact Information

Website
www.iambic.ai
Formerly Known As
Entos
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 5627 Oberlin Drive
  • Suite 120
  • San Diego, CA 92121
  • United States
+1 (619)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Stock Exchange
NAS
Vertical(s)
Digital Health, Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Corporate Office
  • 5627 Oberlin Drive
  • Suite 120
  • San Diego, CA 92121
  • United States
+1 (619)

Iambic Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Iambic Stock Performance

As of 13-Nov-2026, Iambic’s stock price is $13.05. Its current market cap is $621M with 47.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.05 $14.84 $9.60 - $25.00 $621M 47.4M 793K -$2.69

Iambic Financials Summary

As of 30-Jun-2026, Iambic has a trailing 12-month revenue of $18.3M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024
Revenue 18,251 9,426 1,194
EBITDA (98,871) (81,215) (52,818)
Net Income (94,246) (77,295) (47,877)
Total Assets 237,196 195,018 155,749
Total Debt 5,189 5,653 6,497
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Iambic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Iambic‘s full profile, request access.

Request a free trial

Iambic Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Iambic‘s full profile, request access.

Request a free trial

Iambic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its pr
Drug Discovery
San Diego, CA
171 As of 2026

Cambridge, MA
 

Millbrae, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Iambic Competitors (12)

One of Iambic’s 12 competitors is Relay Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Relay Therapeutics Formerly VC-backed Cambridge, MA
Eikon Therapeutics Formerly VC-backed Millbrae, CA
Generate Biomedicines Formerly VC-backed Somerville, MA
Recursion Pharmaceuticals Formerly VC-backed Salt Lake City, UT
Terray Therapeutics Venture Capital-Backed Monrovia, CA
You’re viewing 5 of 12 competitors. Get the full list »

Iambic Patents

  • 43

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 30

    Pending

  • Expiring in next 12 mo

Iambic Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026222136-A1 Isotopically enriched kif modulator compounds and methods of use Pending 16-Apr-2025
WO-2026222221-A1 Methods for identifying patients for treatment with a kif18a inhibitor Pending 16-Apr-2025
US-20260116881-A1 Kif modulator compounds and methods of use Pending 11-Oct-2024
US-20260265254-A1 Kif modulator compounds and methods of use Pending 11-Oct-2024
WO-2026080759-A1 Kif modulator compounds and methods of use Pending 11-Oct-2024 A61P35/00
To view Iambic’s complete patent history, request access »

Iambic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Iambic FAQs

  • When was Iambic founded?

    Iambic was founded in 2019.

  • Where is Iambic headquartered?

    Iambic is headquartered in San Diego, CA.

  • What is the size of Iambic?

    Iambic has 171 total employees.

  • What industry is Iambic in?

    Iambic’s primary industry is Drug Discovery.

  • Is Iambic a private or public company?

    Iambic is a Public company.

  • What is Iambic’s stock symbol?

    The ticker symbol for Iambic is IAM.

  • What is the current stock price of Iambic?

    As of 13-Nov-2026 the stock price of Iambic is $13.05.

  • What is the current market cap of Iambic?

    The current market capitalization of Iambic is $621M.

  • What is Iambic’s current revenue?

    The trailing twelve month revenue for Iambic is $18.3M.

  • Who are Iambic’s competitors?

    Relay Therapeutics, Eikon Therapeutics, Generate Biomedicines, Recursion Pharmaceuticals, and Terray Therapeutics are some of the 12 competitors of Iambic.

  • What is Iambic’s annual earnings per share (EPS)?

    Iambic’s EPS for 12 months was -$2.69.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process